Non-neuropathic heredofamilial amyloidosis digital illustration

Non-neuropathic heredofamilial amyloidosis Save


ICD-10 code: E85.0

Disease category: E85: Amyloidosis

Non-neuropathic Heredofamilial Amyloidosis: A Rare Genetic Disorder

Non-neuropathic heredofamilial amyloidosis, also known as familial amyloid polyneuropathy, is a rare genetic disorder characterized by the accumulation of abnormal protein deposits in various organs and tissues of the body. This condition is inherited in an autosomal dominant manner, meaning that an affected individual has a 50% chance of passing the mutated gene to their offspring.

The primary protein involved in non-neuropathic heredofamilial amyloidosis is transthyretin (TTR), which is primarily produced by the liver. Mutations in the TTR gene can cause the protein to misfold, leading to the formation of amyloid fibrils that deposit in organs such as the heart, kidneys, liver, and gastrointestinal tract. These deposits disrupt the normal functioning of the affected organs, leading to a wide range of symptoms.

Non-neuropathic heredofamilial amyloidosis can manifest in various ways, depending on the organs affected. Common symptoms may include heart palpitations, shortness of breath, fatigue, dizziness, gastrointestinal disturbances, and kidney dysfunction. The age of onset and severity of symptoms can vary greatly among individuals, even within the same family.

Diagnosing non-neuropathic heredofamilial amyloidosis can be challenging due to its rarity and the similarity of symptoms with other conditions. However, a combination of clinical evaluation, genetic testing, and imaging studies can help in reaching a definitive diagnosis.

  1. Clinical evaluation: A thorough medical history and physical examination can provide important clues for diagnosing non-neuropathic heredofamilial amyloidosis.
  2. Genetic testing: Identifying specific mutations in the TTR gene through genetic testing can confirm the diagnosis.
  3. Imaging studies: Imaging techniques such as echocardiography, magnetic resonance imaging (MRI), and nuclear scintigraphy can help visualize amyloid deposits in affected organs.

Managing non-neuropathic heredofamilial amyloidosis involves a multidisciplinary approach to address the various organ involvements and symptom management. However, it's important to note that this article does not cover specific treatment options.

In conclusion, non-neuropathic heredofamilial amyloidosis is a rare genetic disorder characterized by abnormal protein deposition in various organs and tissues. Prompt diagnosis and proper management are crucial for improving the quality of life of affected individuals. If you suspect you or a family member may have this condition, it is important to consult with a healthcare professional for a thorough evaluation and appropriate guidance.

Treatment of Non-neuropathic heredofamilial amyloidosis:

Treatment Options for Non-neuropathic Heredofamilial Amyloidosis

Non-neuropathic heredofamilial amyloidosis is a rare genetic disorder characterized by the buildup of abnormal proteins in various organs of the body. Although there is currently no cure for this condition, there are several treatment options available to manage the symptoms and slow down the progression of the diseas...

To see full information about treatment please Sign up or Log in